Trials / Unknown
UnknownNCT02044692
The Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) Patients
The Long-term Safety of Hunterase (Idursulfase-beta) in Hunter Syndrome(Mucopolysaccharidosis II) Patients
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 34 (estimated)
- Sponsor
- Green Cross Corporation · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the long term safety and efficacy of once weekly dosing of idurasulfase-beta 0.5mg/kg administered in Hunter Syndrome(Mucopolysaccharidosis II) Patients
Conditions
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2020-01-01
- Completion
- 2020-01-01
- First posted
- 2014-01-24
- Last updated
- 2014-06-20
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02044692. Inclusion in this directory is not an endorsement.